Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.83 |
| ▸ | DHCR24 | Q15392 | 11/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | OSBP | P22059 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869826 | 1.00 | MEN1 (0.83) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL12869831 | 0.92 | MEN1 (0.83) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL28606202 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL1957035 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL5571689 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL25035233 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL15529878 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL187737 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL22099724 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT | |
| SCHEMBL14360754 | 0.91 | USP2 (1.00) | MEN1KMT2AALDH1A1USP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2377874-B1 | Compositions comprising a lophenol | MORINAGA MILK INDUSTRY CO LTD (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-8470807-B2 | Antioxidant | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2377874-A1 | ANTIOXIDANT | Morinaga Milk Industry Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110212931-A1 | ANTIOXIDANT | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212931-A1 | ANTIOXIDANT | GPX4, GPX1, LPO | MEN1 4817/4885KMT2A 3798/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.